Understanding Cancer Drug Names and Treatment Acronyms
When you first hear the name of a cancer treatment, it can seem long, complicated, and difficult to remember. However, these names follow specific naming conventions that help healthcare professionals identify the medicines involved and how they work.
Chemotherapy Regimen Names
Cancer treatments are often given as a regimen, which is a planned combination of one or more drugs.
Single-Drug (Monotherapy) Regimens
When only one drug is used, the regimen is usually referred to as a monotherapy. Examples include:
- Doxorubicin monotherapy
- Axicabtagene ciloleucel monotherapy
- S-1 monotherapy
- Trifluridine and tipiracil monotherapy
Two-Drug Regimens
When two drugs are used together, the regimen may be written out in full or abbreviated using the first letters of each medicine.
Examples include:
- Carboplatin and Paclitaxel (CP)
- Cisplatin and radiation therapy (RT)
- Docetaxel and Bevacizumab
- Lenalidomide and Dexamethasone (Rd)
Multi-Drug Regimens
Many cancer treatments combine three or more medicines. These regimens are often known by acronyms made from the names of the drugs involved.
Some common examples are:
- ABVD – Doxorubicin (Adriamycin), Bleomycin, Vinblastine, and Dacarbazine
- FOLFIRI – Folinic acid (Leucovorin), Fluorouracil (5-FU), and Irinotecan
- R-CHOP – Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
- Dara-Kd – Daratumumab, Carfilzomib, and Dexamethasone
While these abbreviations may seem confusing at first, they provide a quick way for healthcare teams to identify a treatment regimen.
Understanding Monoclonal Antibody Names
Monoclonal antibodies are targeted therapies designed to recognise and attack specific cancer cells. Many of these medicines end in “-mab”, which indicates they are monoclonal antibodies.
Parts of the name can provide information about the drug:
- -tu- indicates the drug targets tumours.
- -ci- indicates a circulatory system target.
- -xi- indicates the antibody is chimeric (part human, part non-human).
- -zu- indicates the antibody is humanised (mostly human).
- -u- indicates the antibody is fully human.
Examples
Trastuzumab
- Tras- = unique prefix
- -tu- = tumour target
- -zu- = humanised antibody
- -mab = monoclonal antibody
Trastuzumab is commonly used to treat HER2-positive breast cancer.
Abciximab
- -ci- = circulatory system target
- -xi- = chimeric antibody
- -mab = monoclonal antibody
Understanding Immunotherapy Names
Immunotherapy uses the body’s immune system to recognise and fight cancer cells.
Some naming patterns include:
- -mab – monoclonal antibodies used in immunotherapy
- -cell – cellular therapies
- -imut – immunotherapy products
Additional parts of the name may describe the type of treatment or its target.
Example
Ipilimumab (Yervoy®) is an immunotherapy that targets CTLA-4, a protein involved in regulating immune responses. The name indicates it is a fully human monoclonal antibody used to enhance the body’s immune response against cancer.
Why Do These Names Matter?
Cancer drug names and regimen acronyms are designed to provide information about the medicines being used and, in some cases, how they work. While the terminology can seem overwhelming, understanding a few common naming patterns can make treatment discussions easier to follow.
If you are unsure about your treatment or have questions about the medicines you are receiving, speak with your treating team. You can also contact the nurses at Bloomhill for additional support and clarification.
References
American Cancer Society. (2026). Immunotherapy. Retrieved June 11, 2026, from https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy.html
American Medical Association. (2026). Cellular and nomenclature therapies naming scheme. Retrieved June 11, 2026, from https://www.ama-assn.org/about/united-states-adopted-names-usan/cellular-noncellular-therapies-naming-scheme
Bionity.com. Nomenclature of monoclonal antibodies. Retrieved June 11, 2026, from https://www.bionity.com/en/encyclopedia/Nomenclature_of_monoclonal_antibodies.html
Cleveland Clinic. (2026). R-CHOP. Retrieved June 11, 2026, from https://my.clevelandclinic.org/health/treatments/r-chop
Hannemann, K. (2026, February 10). What is the FOLFIRI chem regimen and how does it work? Drugs.com. Retrieved June 11, 2026, from https://www.drugs.com/medical-answers/what-folfiri-chemo-regimen-how-work-3579914/
Hannemann, K. (2026, May 15). What is ABVD chemo regimen and how is it used for lymphoma? Drugs.com. Retrieved from https://www.drugs.com/medical-answers/what-abvd-chemo-regimen-how-used-lymphoma-3579886/
HemOnc.org. (2026, June 6). Regimen naming conventions (nomenclature). Retrieved June 11, 2026, from https://hemonc.org/wiki/Regimen_naming_conventions_(nomenclature)
Patient Education Sheets. (2026). Daratumumab, Carfilzomib and Dexamethasone (Dara-Kd). Retrieved June 11, 2026, from https://ncoda90f71ba7b4.blob.core.windows.net/blobncoda90f71ba7b4/wp-content/uploads/2025/10/PES.daratumumab-and-Kd.pdf
Rubenstein, S. M., Yang, P. C., Cowan, A. J., Warner, J. L. (2019). Standardising chemotherapy regimen nomenclature: A proposal and evaluation of the HemOnc and National Cancer Institute thesaurus regimen content. Journal of Clinical Oncology. Retrieved June 09, 2026, from https://ascopubs.org/doi/pdfdirect/10.1200/CCI.19.00122
Wikipedia. (2026, February 5). Nomenclature of monoclonal antibodies. Retrieved June 11, 2026, from https://en.wikipedia.org/wiki/Nomenclature_of_monoclonal_antibodies
Please contact our Nurses on 07 5445 5794 or [email protected] if you have any questions.
All information provided by Bloomhill is mainly based on research from the Qld Cancer Council and best practice guidelines. Our model of care utilizes the Clinical Oncology Society of Australia (COSA) domains of wellness along with available clinical evidence. Always consult your care team regarding matters that affect your health. This is a guide intended for information only.
